Lung Cancer Management最新文献_第7页

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? 化疗和/或免疫检查点抑制剂在非小细胞肺癌一线:什么是最好的方法?

IF 2.8

Lung Cancer Management Pub Date : 2020-02-12 DOI: 10.2217/lmt-2019-0018

Luigi Della Gravara, Ciro Battiloro, Rosa Cantile, Antonietta Letizia, Fabiana Vitiello, Vincenzo Montesarchio, Danilo Rocco

引用次数: 15

Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation. 化疗后接受检查点抑制剂的III期非小细胞肺癌患者的实际挑战。

IF 2.8

Lung Cancer Management Pub Date : 2020-02-06 DOI: 10.2217/lmt-2020-0001

Nikhil A Shukla, Nasser H Hanna

{"title":"Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation.","authors":"Nikhil A Shukla, Nasser H Hanna","doi":"10.2217/lmt-2020-0001","DOIUrl":"https://doi.org/10.2217/lmt-2020-0001","url":null,"abstract":"NSCLC accounts for 80% of all lung cancer diagnoses, and approximately a third of patients present with locally advanced (stage III) disease [1]. The optimal therapy for fit patients with unresectable and/or inoperable stage III disease has evolved over the last three decades from radiation alone to sequential chemoradiation (CRT) to concurrent CRT followed by checkpoint inhibitor therapy (CPI). The recently reported PACIFIC trial generated a paradigm shift in the treatment of such patients, with a 3-year overall survival (OS) of 57% for patients receiving consolidation durvalumab compared with 43.5% for those receiving placebo [2–4]. Similar outcomes were reported with consolidation pembrolizumab in a Hoosier Cancer Research Network (HCRN) Phase II Trial [5]. In this article, we explore key clinical challenges that arise when treating patients with consolidation CPI after CRT for patients with stage III NSCLC; namely, the management of CPI-related pneumonitis, timing of consolidation CPI and their role in patients with PD-L1 TPS <1% and distinguishing local progression versus pseudoprogression.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT23"},"PeriodicalIF":2.8,"publicationDate":"2020-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer. 支气管内凸超声:同一枚硬币，两面。非小细胞肺癌具有挑战性的活检和分期。

IF 2.8

Lung Cancer Management Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0008

Konstantinos Sapalidis, Konstantinos Romanidis, Panagoula Oikonomou, Paul Zarogoulidis, Athanasios Katsaounis, Aikaterini Amaniti, Nikolaos Michalopoulos, Charilaos Koulouris, Kosmas Tsakiridis, Dimitrios Giannakidis, Isaak Kesisoglou, Aris Ioannidis, Iason Nikolaos-Katsios, Anastasios Vagionas, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Alexandru Marian Goganau, Christoforos Kosmidis

{"title":"Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer.","authors":"Konstantinos Sapalidis, Konstantinos Romanidis, Panagoula Oikonomou, Paul Zarogoulidis, Athanasios Katsaounis, Aikaterini Amaniti, Nikolaos Michalopoulos, Charilaos Koulouris, Kosmas Tsakiridis, Dimitrios Giannakidis, Isaak Kesisoglou, Aris Ioannidis, Iason Nikolaos-Katsios, Anastasios Vagionas, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Alexandru Marian Goganau, Christoforos Kosmidis","doi":"10.2217/lmt-2019-0008","DOIUrl":"https://doi.org/10.2217/lmt-2019-0008","url":null,"abstract":"<p><p>Lung cancer is still diagnosed at a late stage due to lack of early disease symptoms. Despite the development of new diagnostic endoscopic tools, such as radial/convex endobronchial ultrasounds (EBUS) and electromagnetic navigation, most patients are still diagnosed at advanced stage disease. Most of the patients refer to their doctor only if they cough blood or their cough changes character. There are challenging cases in the diagnosis and staging of a patient, such as the one that we will present. We present a case of lung cancer that was diagnosed through a biopsy from the main lesion, with access from the esophagus, through transbronchial needle aspiration with EBUS, under general anesthesia and intubation. Staging with transbronchial needle aspiration with EBUS was also performed at the same session.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 4","pages":"LMT20"},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? 免疫检查点抑制剂在非小细胞肺癌中的再挑战：不同的情况有不同的解决方案？

IF 2.8

Lung Cancer Management Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0012

Giulio Metro, Diego Signorelli

引用次数: 0

Inhaled chemotherapy adverse effects: mechanisms and protection methods. 吸入化疗不良反应:机制及保护方法。

IF 2.8

Lung Cancer Management Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0007

Chrysanthi Sardeli, Paul Zarogoulidis, Christoforos Kosmidis, Aikaterini Amaniti, Athanasios Katsaounis, Dimitrios Giannakidis, Charilaos Koulouris, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Nikolaos Michalopoulos, Kosmas Tsakiridis, Konstantinos Romanidis, Panagoula Oikonomou, Konstantina Mponiou, Anastasios Vagionas, Alexandru Marian Goganau, Isaak Kesisoglou, Konstantinos Sapalidis

引用次数: 13

Can tumor mutational burden determine the most effective treatment for lung cancer patients? 肿瘤突变负担能否决定肺癌患者最有效的治疗方法?

IF 2.8

Lung Cancer Management Pub Date : 2020-01-14 DOI: 10.2217/lmt-2019-0013

Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Tao Wu, Xiaoqin Sun, Kai Wu, Xue-Song Liu

引用次数: 4

Identifying successful biomarkers for patients with non-small-cell lung cancer 非小细胞肺癌癌症患者的成功生物标志物鉴定

IF 2.8

Lung Cancer Management Pub Date : 2019-11-14 DOI: 10.2217/lmt-2019-0009

A. Friedlaender, J. Bauml, G. Banna, A. Addeo

引用次数: 6

Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods 非小细胞肺癌的活检和再活检:当前和未来的方法

IF 2.8

Lung Cancer Management Pub Date : 2019-10-17 DOI: 10.2217/lmt-2019-0006

P. Zarogoulidis, C. Kosmidis, V. Fyntanidou, Z. Aidoni, K. Tsakiridis, Charilaos Koulouris, N. Michalopoulos, Anastasios Barmpas, Hai-dong Huang, C. Bai, W. Hohenforst-Schmidt, K. Sapalidis

引用次数: 1

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study 阿法替尼治疗化疗后携带常见EGFR突变的局部晚期/转移性NSCLC：一项IV期研究

IF 2.8

Lung Cancer Management Pub Date : 2019-09-02 DOI: 10.2217/lmt-2019-0004

S. Thongprasert, Sarayut Lucien Geater, D. Clement, A. Abdelaziz, J. Reyes-Igama, D. Jovanovic, A. Alexandru, M. Schenker, V. Sriuranpong, P. Serwatowski, S. Suresh, A. Cseh, R. Gaafar

引用次数: 3

Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity? 神经内分泌阴性的小细胞肺癌和WT RB1型的大细胞神经内分泌癌是同一实体的两面吗?

IF 2.8

Lung Cancer Management Pub Date : 2019-08-21 DOI: 10.2217/lmt-2019-0005

D. Sonkin, Anish Thomas, B. Teicher

引用次数: 20